GHSI - Guardion Health Sciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.3400
+1.3800 (+143.75%)
As of 1:47PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.9600
Open1.4200
Bid2.4300 x 1100
Ask2.4600 x 1400
Day's Range1.3000 - 3.0500
52 Week Range0.9000 - 4.0000
Volume29,006,856
Avg. Volume52,306
Market Cap52.63M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.3350
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire7 hours ago

    Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), announced that it has received a patent from the Patents Registry in Hong Kong (Hong Kong Patent No. HK1204758 titled “Apparatus for Use in the Measurement of Macular Pigment Optical Density and/or Lens Optical Density of an Eye”) for its proprietary medical device, the MapcatSF®. The MapcatSF® measures the macular pigment density in the human eye, thus facilitating treatment for several ocular conditions and diseases that affect a large number of patients. Dr David Evans, Guardion’s Chief Science Officer, commenting on the granting of this patent by Hong Kong, stated, “The granting of this patent in Honk Kong represents an important step in Guardion’s process to expand into the large Asian markets, where evidenced-based eye care is of great interest to both physicians and consumers.

  • GlobeNewswire27 days ago

    Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, announced that it has received a patent from the European Union (European Patent No. 2,811,892 titled “Apparatus for Use in the Measurement of Macular Pigment Optical Density and/or Lens Optical Density of an Eye”) for its proprietary medical device, the MapcatSF®. The MapcatSF® measures the macular pigment density in the human eye, thus facilitating treatment for several ocular conditions and diseases that affect a large number of patients.

  • GlobeNewswirelast month

    Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’

    In an IRB-approved trial conducted at the New York Eye and Ear Infirmary, the parent compound of GlaucoCetin, GlaucoHealth, designed by Robert Ritch, MD, successfully reversed mitochondrial dysfunction in patients with glaucoma. San Diego, CA, June 04, 2019 (GLOBE NEWSWIRE) --  Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the launch of the Company’s second ocular health formula.

  • GlobeNewswire2 months ago

    Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2

    The AREDS 2 Group showed no statistical change. San Diego, CA, May 09, 2019 (GLOBE NEWSWIRE) --  Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the results of a study from research scientists at the Western University College of Optometry to clinically evaluate the visual benefits of the Company’s micronized liquid formula Lumega-Z as compared to the AREDS 2 softgel supplement in individuals with retinal drusen and at risk of developing Age-Related Macular Degeneration (AMD).

  • GlobeNewswire2 months ago

    Guardion's Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the results of a study from research scientists at the University of Texas, San Antonio (USTA), Texas, on the effects of the Company’s Lumega-Z medical food on pericentral FDT (i.e.

  • GlobeNewswire3 months ago

    Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China

    Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced that it was recently notified by the State Intellectual Property Office of the People’s Republic of China (“China”) that it has been granted trademark registrations in China for its proprietary medical food, Lumega-Z (Registration No. 27151643), and for its proprietary medical device, the MapcatSF (Registration No. 27151644). The trademark registration for Lumega-Z is effective from November 7, 2018 to November 6, 2028, and the trademark registration for the MapcatSF is effective from October 28, 2018 to October 27, 2028.

  • GlobeNewswire3 months ago

    Results of Lumega-Z Data to be Presented at ARVO

    Guardion Health Sciences, Inc.’s (the “Company”) Scientific Advisory Board member, Dr. William Sponsel will be presenting an abstract at the Association for Research in Vision and Ophthalmology (“ARVO”) 2019 Annual Meeting in Vancouver, Canada, which will be held from April 28, 2019 to May 2, 2019. The study assessed the potential utility of the Company’s medical food product, Lumega-Z, which is designed to restore the macular protective pigment layer. The abstract concludes that in patients who had ordered 12 consecutive month’s supply of Lumega-Z, Lumega-Z treatment was associated with significant improvement in visual field function among patients with severe glaucoma who had previously shown degeneration despite having had excellent intraocular pressure control.

  • WallachBeth Capital Announces Completion of the $5 Million IPO for Guardion Health Services
    PR Newswire3 months ago

    WallachBeth Capital Announces Completion of the $5 Million IPO for Guardion Health Services

    JERSEY CITY, N.J. , April 11, 2019 /PRNewswire/ -- WallachBeth Capital, a leading provider of capital markets and institutional execution services, announced the closing of the initial public offering ...

  • GlobeNewswire3 months ago

    Guardion Health Sciences, Inc. Announces Closing of Initial Public Offering

    Guardion Health Sciences Inc. (“Guardion”) (GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced that it closed its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for total gross proceeds of $5.0 million, before deducting underwriting discounts and commissions and other offering costs and expenses payable by Guardion. In addition, Guardion has granted the underwriters a 45-day option to purchase up to 187,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.

  • Business Wire3 months ago

    Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering

    Guardion Health Sciences Inc. (“Guardion”) (Nasdaq:GHSI), an ocular health sciences and technologies company that develops, formulates and distributes condition-specific medical foods and testing technologies supported by evidence-based protocols, today announced the pricing of its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share for total gross proceeds of $5.0 million, before deducting underwriting discounts and commissions and other offering costs and expenses payable by Guardion. In addition, Guardion has granted the underwriters a 45-day option to purchase up to 187,500 additional shares of common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments, if any.